newsfilter
← Latest News
ACCESS Newswire·

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Program Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo